Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 118)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Iron |
Approved |
Phase 4 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
2 |
|
Hepcidins |
|
Phase 4 |
|
|
|
3 |
|
Mitomycin |
Approved |
Phase 2, Phase 3 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
4 |
|
Nicotine |
Approved |
Phase 3 |
|
54-11-5 |
942 89594 |
Synonyms:
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+)-Nicotine
(+-)-Nicotine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(RS)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
a -N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
Bitartrate, nicotine
Black Leaf
Black Leaf 40
Campbell's Nico-Soap
Commit
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
Habitrol
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
|
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Niagara P.A. Dust
NICABATE
Nicocide
Nicoderm
NICODERM CQ
Nico-Dust
Nico-Fume
NICOPASS
NICOPATCH
Nicorette
NICORETTE INVISI
Nicorette Plus
Nicorette®|Nicotrol®
Nicotin
Nicotina
Nicotine
Nicotine alkaloid
Nicotine betadex
Nicotine bitartrate
Nicotine polacrilex
Nicotine tartrate
NICOTINELL CLASSIC
NICOTINELL SUPPORT
NICOTINELL TTS 10
NICOTINELL TTS 20
NICOTINELL TTS 30
NICOTROL
NICOTROL INHALER
NICOTROL NS
Nic-Sal
Nikotin
Nikotyna
NIQUITIN
NIQUITIN CLR
NIQUITIN MINIS CHERRY
NIQUITIN MINIS MINT
NIQUITIN MINIS ORANGE
NIQUITIN MINT
NIQUITIN PRE-QUIT
NIQUITIN STRIPS MINT
Ortho N-4 Dust
Ortho N-5 Dust
PROSTEP
R)-(+)-Nicotine
STOPPERS
STUBIT
Tartrate, nicotine
Tendust
|
|
5 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
6 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Β-aminoethanol
Β-aminoethyl alcohol
Β-ethanolamine
Β-hydroxyethylamine
|
|
7 |
|
Chlorotrianisene |
Investigational, Withdrawn |
Phase 3 |
|
569-57-3 |
11289 |
Synonyms:
Chloortrianisestrol
Chlorestrolo
Chlorotrianisene
Chlorotrianisenum
Chlorotrianisine
Chlorotrianizen
Chlortrianisen
Chlortrianisene
|
Chlortrianisenum
Chlortrianisestrol
Chlortrianisoestrolum
Chlortrianizen
Clorotrianiseno
NSC-10108
TACE
TRIANISESTROL
|
|
8 |
|
Calciferol |
|
Phase 3 |
|
|
|
9 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
10 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
11 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
12 |
|
Antibodies |
|
Phase 3 |
|
|
|
13 |
|
Hematinics |
|
Phase 3 |
|
|
|
14 |
|
Formyltetrahydrofolates |
|
Phase 3 |
|
|
|
15 |
|
Tetrahydrofolates |
|
Phase 3 |
|
|
|
16 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
17 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
18 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
19 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
20 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
21 |
|
Vancomycin |
Approved |
Phase 2 |
|
1404-90-6 |
14969 |
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2SP,3.5SA,2.6SP)-O(4.2),C(3.4)
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-b-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-b-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
Abbott brand OF vancomycin hydrochloride
AB-vancomycin
Azupharma brand OF vancomycin hydrochloride
C(5.4),O(4.6)
Cell pharm brand OF vancomycin hydrochloride
Chiesi brand OF vancomycin hydrochloride
Combino brand OF vancomycin hydrochloride
Curasan brand OF vancomycin hydrochloride
Dakota brand OF vancomycin hydrochloride
Diatracin
Dista brand OF vancomycin hydrochloride
Eli lilly brand OF vancomycin hydrochloride
Hexal brand OF vancomycin hydrochloride
Hydrochloride, vancomycin
Lilly brand OF vancomycin hydrochloride
MIP brand OF vancomycin hydrochloride
Norman brand OF vancomycin hydrochloride
Ratiopharm brand OF vancomycin hydrochloride
|
Sulfate, vancomycin
Vanco azupharma
Vanco-cell
Vancocin
Vancocin HCL
Vancocine
VANCOLED
Vancomicin
Vancomicina
Vancomicina abbott
Vancomicina chiesi
Vancomicina combino phar
Vancomicina norman
VANCOMYCIN
Vancomycin HCL
Vancomycin hexal
Vancomycin hydrochloride
Vancomycin lilly
Vancomycin phosphate (1:2)
Vancomycin phosphate (1:2), decahydrate
Vancomycin sulfate
Vancomycine
Vancomycine dakota
Vancomycin-ratiopharm
Vancomycinum
VANCOR
Vanco-saar
|
|
22 |
|
Framycetin |
Approved, Experimental, Vet_approved |
Phase 2 |
|
1404-04-2, 119-04-0, 3947-65-7 |
413349 8378 |
Synonyms:
2-desoxy-4-O-(2,6-diamino-2,6-didesoxy-α-D-glucopyranosyl)-D-streptamin
4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-2-deoxy-D-streptamine
Antibiotic 10676
ANTIBIOTIQUE EF 185
Biosol
Bykomycin
Caswell no. 595
Dekamycin V
Endomixin
Fradiomycin
Fradiomycin b
Fradiomycin sulfate
Framicetina
Framycetin
Framycetin sulfate
Framycetine
Framycétine
Framycetinum
Fraquinol
FRM
Kaomycine
Lidamycin Creme
Myacine
Myacyne
Mycifradin
Mycifradin-N
Myciguent
NEAMINE
Nebramycin X
Negamicin
|
Neobiotic
Neobrettin
Neofracin
Neo-Fradin
Neolate
Neo-Mantle Creme
Neomicina
Neomix
NEOMYCIN
Neomycin A
Neomycin b
Neomycin b sulfate
Neomycin palmitate
Neomycin sulfate
Neomycin sulphate
Neomycin trisulfate salt hydrate
NEO-RX
Neo-Rx®|neomycin sulfate
Neosulf
Nivemycin
Palmitate, neomycin
Soframycin
Sulfate, fradiomycin
Sulfate, framycetin
Sulfate, neomycin
Sulfate, neomycin b
Tuttomycin
USAF CB-19
Vonamycin
Vonamycin Powder V
|
|
23 |
|
Metronidazole |
Approved |
Phase 2 |
|
443-48-1, 69198-10-3 |
4173 |
Synonyms:
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(Β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(Β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(Β-oxyethyl)-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitroimidazole-1-ethanol
ACEA
Acromona
ANABACT
Anagiardil
Apo-Metronidazole
Arilin
Atrivyl
BAY-5360
Bayer 5360
BAYER-5360
Bexon
Clont
Cont
Danizol
Deflamon
Deflamon-Wirkstoff
DRAZIFON
Efloran
ELYZOL
Entizol
Eumin
Flagemona
Flagesol
Flagil
Flagyl
FLAGYL 375
FLAGYL COMPAK
FLAGYL ER
Flagyl I.V.
FLAGYL I.V. RTU IN PLASTIC CONTAINER
FLAGYL-400
FLAGYL-S
Flegyl
Fossyol
Giatricol
Gineflavir
Hydrochloride, metronidazole
Klion
Klont
Meronidal
Methronidazole
Metric
METRIC 21
Metro Cream
Metro I.V.
Metro I.V. In Plastic Container
METRO IV
METROCREAM
Metrodzhil
MetroGel
Metrogel-vaginal
Metrogyl
Metrolag
METROLOTION
METROLYL
|
METROMIDOL
Metronidaz
Metronidazol
METRONIDAZOLE
Métronidazole
Metronidazole benzoate
Metronidazole Hcl
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazolo
Metronidazolum
METROSA
METROTOP
Mexibol
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
Neo-Tric
NEUTRATOP
Nida
Nidagel
Noritate
Noritic acid
NORZOL
Novonidazol
NSC-50364
NSC-69587
NUVESSA
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
PROTOSTAT
Rathimed
ROSICED
ROZEX
RP-8823
Sanatrichom
Satric
Takimetol
Trichazol
Trichex
Tricho Cordes
Trichocide
Tricho-Gynaedron
Trichomol
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
Vagilen
Vagimid
VAGINYL
VANDAZOLE
Vertisal
Wagitran
ZADSTAT
ZIDOVAL
ZYOMET
|
|
24 |
|
Obinutuzumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
949142-50-1 |
|
Synonyms:
AFUTUZUMAB
GA101
GA-101|GA101|Gazyva®
GAZYVARO
HUMAB<CD20>
HUMABCD20
|
OBINUTUZUMAB
R-7159
RG-7159
RO-5072759
RO-5072759 HUMAB<CD20>
|
|
25 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
26 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
27 |
|
Temozolomide |
Approved, Investigational |
Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
28 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
29 |
|
Dimethyl sulfoxide |
Approved, Vet_approved |
Phase 2 |
|
67-68-5 |
679 |
Synonyms:
(CH3)2SO
(Methylsulfinyl)methane
DIMETHYL SULFOXIDE
Dimethyl sulfoxixde
Dimethyl sulfur oxide
Dimethyl sulphoxide
Dimethyl sulphur oxide
Dimethyl sulpoxide
Dimethyli sulfoxidum
Dimethyli sulphoxidum
Dimethylsulfoxid
Dimethylsulfoxide
Dimethylsulfoxyde
Diméthylsulfoxyde
Dimethylsulphinyl
Dimethylsulphoxid
Dimethylsulphoxide
Dimethylsulphoxyde
Dimetil sulfoxido
Dimetil sulfóxido
Dimetil sulphoxido
Dimexide
DMSO
DOMOSO
|
INFILTRINA
Merckle brand OF dimethyl sulfoxide
Methylsulfinylmethane
Methylsulphinylmethane
NSC-763
Research ind. corp. brand 1 OF dimethyl sulfoxide
Research ind. corp. brand 2 OF dimethyl sulfoxide
Rheumabene
Rimso
rimso 100
Rimso 50
Rimso50
Rimso-50
S(O)Me2
Sclerosol
Shire brand OF dimethyl sulfoxide
SQ-9453
Sulfinylbis(methane)
Sulfoxide, dimethyl
Sulphinylbis(methane)
Sulphoxide, dimethyl
SYNTEXAN
Zymso
|
|
30 |
|
Dabrafenib |
Approved, Investigational |
Phase 2 |
|
1195765-45-7 |
44462760 |
Synonyms:
DABRAFENIB
DRB436
GSK2118436
GSK-2118436
|
GSK2118436|GSK2118436A|Tafinlar®
GSK2118436a
GSK-2118436A
TAFINLAR
|
|
31 |
|
Tremelimumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
32 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
33 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
34 |
|
Hydroquinone |
Approved, Investigational |
Phase 2 |
|
123-31-9 |
785 |
Synonyms:
1,4-Benzenediol
1,4-Benzoquinol
1,4-Dihydroxy-benzeen
1,4-Dihydroxybenzen
1,4-Dihydroxybenzene
1,4-Dihydroxy-benzol
1,4-Diidrobenzene
1,4-p-Benzenediol
1,4-Phenylenediol
4-Hydroxyphenol
a-Hydroquinone
alpha-Hydroquinone
Artra
Benzene-1,4-diol
Benzohydroquinone
Benzoquinol
beta-Quinol
Black and white
BLACK AND WHITE BLEACHING CREAM
b-Quinol
CHEMBL537
Dihydroquinone
Dihydroxybenzene
Eldopaque
Eldopaque forte
Eldoquin
Eldoquin forte
Esoterica
Hidroquilaude
Hidroquin
Hidroquinona isdin
Hydrochinon
Hydrochinone
Hydroquinol
Hydroquinole
HYDROQUINONE
Hydroquinone for synthesis
Hydroquinone GR
|
Hydroquinone, copper (1+) salt
Hydroquinone, lead (2+) salt (2:1)
Hydroquinone, monocopper (2+) salt
Hydroquinoue
ICN brand 1 OF hydroquinone
ICN brand 2 OF hydroquinone
ICN brand 3 OF hydroquinone
ICN brand 4 OF hydroquinone
Idrochinone
Licostrata
Lustra
Melanasa
Melanex
Melpaque
Melquin
NCI-C55834
Neostrata HQ
NSC-9247
p-Benzenediol
p-Dihydroquinone
p-Dihydroxybenzene
P-Dioxobenzene
p-Dioxybenzene
Phiaquin
p-Hydroquinone
P-Hydroxybenzene
p-Hydroxyphenol
Plough brand 1 OF hydroquinone
Plough brand 2 OF hydroquinone
p-Phenylenediol
p-Quinol
Quinol
Solaquin
Solaquin forte
Stratus brand 1 OF hydroquinone
Stratus brand 2 OF hydroquinone
Ultraquin
|
|
35 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
36 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
37 |
|
Trifluridine |
Approved, Investigational |
Phase 2 |
|
70-00-8 |
6256 |
Synonyms:
2'-Deoxy-5-(trifluoromethyl)uridine
5 Trifluoromethyl 2' deoxyuridine
5-(Trifluoromethyl)deoxyuridine
5-Trifluoromethyl-2'-deoxyuridine
5-Trifluoromethyl-2-deoxyuridine
Allergan brand OF trifluridine
Elcon brand OF trifluridine
F3DThd
F3T
F₃T
F3TDR
Fluridine
Mann brand OF trifluridine
Monarch brand OF trifluridine
NSC-529182
NSC-75520
T.F.T.
TFDU
TFT
|
TFT Ophtiole
THE694
Tramedico brand OF trifluridine
Triflumann
Trifluoridine
Trifluoromethyldeoxyuridine
Trifluorothymidine
Trifluorothymine deoxyriboside
Trifluridin
Trifluridina
Trifluridina [INN-Spanish]
Trifluridine
Trifluridine [USAN:INN]
Trifluridinum
Trifluridinum [INN-Latin]
TRIHERPINE
Viromidin
Virophta
Viroptic
|
|
38 |
|
Tucatinib |
Approved, Investigational |
Phase 2 |
|
937263-43-9 |
51039094 |
Synonyms:
ARRY-380
ARRY-380|Example 11 [WO2007059257A2]|ONT-380|Tukysa®
|
|
|
39 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
40 |
|
Atezolizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
41 |
|
Durvalumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
42 |
|
Dopamine |
Approved |
Phase 1, Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
43 |
|
Metamfetamine |
Approved, Illicit, Withdrawn |
Phase 1, Phase 2 |
|
537-46-2 |
10836 |
Synonyms:
(+ )-Methylamphetamine
(+)-(S)-Deoxyephedrine
(+)-(S)-N-a-Dimethylphenethylamine
(+)-(S)-N-alpha-Dimethylphenethylamine
(+)-(S)-N-Α-dimethylphenethylamine
(+)-(S)-P-Α-DIMETHYLPHENETHYLAMINE
(+)-2-(N-Methylamino)-1-phenylpropane
(+)-Methamphetamine
(+)-Methylamphetamine
(+)-N,alpha-Dimethyl-beta-phenylethylamine
(+)-N,alpha-Dimethylphenethylamine
(+)-N-Methylamphetamine
(2S)-N-Methyl-1-phenylpropan-2-amine
(AlphaS)-N,a-dimethylbenzeneethanamine
(AlphaS)-N,alpha-dimethylbenzeneethanamine
(AlphaS)-N,α-dimethylbenzeneethanamine
(S)-(+)-Deoxyephedrine
(S)-(+)-Methamphetamine
(S)-(+)-N,alpha,Dimethylphenethylamine
(S)-Methamphetamine
(S)-Methylamphetamine
(S)-N,a-Dimethylbenzeneethanamine
(S)-N,alpha-Dimethylbenzeneethanamine
(S)-N,alpha-Dimethylbenzeneethanoamine
(S)-N,Α-dimethylbenzeneethanamine
(ΑS)-N,Α-DIMETHYLBENZENEETHANAMINE
1-Phenyl-2-methylamino-propan [German]
1-Phenyl-2-methylaminopropane
2S-(+)-Methamphetamine
Abbott brand OF methamphetamine hydrochloride
D-(S)-Methamphetamine
d-1-Phenyl-2-methylaminopropan [German]
D-1-Phenyl-2-methylaminopropane
D-Deoxyephedrine
D-Desoxyephedrine
Deoxyephedrine
Desoxyephedrine
Desoxyephedrine hydrochloride
Desoxyn
Desyphed
Desyphed hydrochloride
Dextromethamphetamine
|
D-Methamphetamine
D-Methylamphetamine
D-N,alpha-Dimethylphenethylamine
D-N-Methylamphetamine
D-Phenylisopropylmethylamine
Hydrochloride, methamphetamine
Ice
J6.362B
Langly brand OF methamphetamine hydrochloride
L-Methamphetamine
Madrine
Metamfetamina [inn-spanish]
Metamfetamine
MÉTAMFÉTAMINE
Metamfetamine-m
Metamfetaminum
Metamfetaminum [inn-latin]
Metamphetamine
Metanfetamina
Metanfetamina [inn-spanish]
Meth
Methamphetamine
Methamphetamine hydrochloride
METHAMPHETAMINE, METHYLAMPHETAMINE
METHAMPHETAMINUM
Methamphetaminum [inn-latin]
Methylamphetamine
Methyl-beta-phenylisopropylamine
Methyl-b-phenylisopropylamine
Methyl-β-phenylisopropylamine
N Methylamphetamine
N-Methyl-1-phenyl-2-propanamine
N-Methylamphetamine
N-methyl-beta-phenylisopropylamin [german]
N-Methyl-beta-phenylisopropylamine
Norodin
NSC-25115
S-(+)-Methamphetamine
S-METHAMPHETAMINE
Speed
Stimulex
|
|
44 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
45 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
46 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
47 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
48 |
|
Sulindac |
Approved, Investigational |
Phase 2 |
|
38194-50-2 |
5352 1548887 |
Synonyms:
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetate
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetate
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
2-[6-Fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]-1-indenyl]acetate
2-[6-Fluoro-2-methyl-3-[(4-methylsulphinylphenyl)methylidene]-1-indenyl]acetate
2-[6-Fluoro-2-methyl-3-[(4-methylsulphinylphenyl)methylidene]-1-indenyl]acetic acid
Aclin
Alphapharm brand OF sulindac
Apo sulin
Apo-sulin
Apotex brand OF sulindac
Arthrobid
Arthrocine
Cahill may roberts brand OF sulindac
Chemia brand OF sulindac
Chibret
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetate
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetate
cis-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetate
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
|
cis-5-Fluoro-2-methyl-1-((p-methylsulphinyl)benzylidene)indene-3-acetate
cis-5-Fluoro-2-methyl-1-((p-methylsulphinyl)benzylidene)indene-3-acetic acid
Clinoril
Clinoril®
Copal
Kenalin
Kendrick brand OF sulindac
Klinoril
Merck brand OF sulindac
Merck sharp and dohme brand OF sulindac
MK-231
Novo sundac
Novopharm brand OF sulindac
Novo-sundac
Nu pharm brand OF sulindac
Nu sulindac
Nu-pharm brand OF sulindac
Nu-sulindac
SULINDAC
Sulindaco
Sulindacum
Sulindal
|
|
49 |
|
Ceritinib |
Approved |
Phase 2 |
|
1032900-25-6 |
57379345 |
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
CERITINIB
CÉRITINIB
Ceritinibum
COMPOUND 15B [PMID 23742252]
compound 15b [PMID 23742252]|LDK378|NVP-LDK378-NX|Zykadia®
|
LDK378
LDK-378
N-{2-[(5-CHLORO-2-{[2-ISOPROPOXY-5-METHYL-4-(PIPERIDIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}PROPANE-2-SULFONAMIDE
NVP-LDK378-NX
NVP-LDK-378-NX
ZYKADIA
|
|
50 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
Interventional clinical trials:
(show top 50)
(show all 143)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron |
Completed |
NCT02057471 |
Phase 4 |
Intravenous ferric carboxymaltose |
2 |
TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy |
Unknown status |
NCT03783559 |
Phase 3 |
TACE;chemotherapy±target therapy |
3 |
A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases |
Unknown status |
NCT03125161 |
Phase 3 |
HAI;chemotherapy ± target therapy |
4 |
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma |
Completed |
NCT02788279 |
Phase 3 |
Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib |
5 |
A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma |
Completed |
NCT00623805 |
Phase 3 |
Bevacizumab;Capecitabine;Oxaliplatin |
6 |
A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma |
Completed |
NCT02390947 |
Phase 3 |
Famitinib;Placebo |
7 |
The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial |
Completed |
NCT00265356 |
Phase 3 |
|
8 |
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study |
Recruiting |
NCT02758951 |
Phase 2, Phase 3 |
|
9 |
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer |
Recruiting |
NCT02997228 |
Phase 3 |
Atezolizumab;Fluorouracil;Leucovorin;Oxaliplatin |
10 |
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) |
Recruiting |
NCT04094688 |
Phase 3 |
Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan |
11 |
Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab |
Terminated |
NCT03300609 |
Phase 3 |
Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine |
12 |
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial |
Withdrawn |
NCT03708536 |
Phase 3 |
S-1;Bevacizumab;Capecitabine |
13 |
Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma |
Unknown status |
NCT00544011 |
Phase 2 |
capecitabine;fluorouracil;irinotecan hydrochloride |
14 |
Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma |
Unknown status |
NCT00027833 |
Phase 2 |
FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium |
15 |
A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment |
Unknown status |
NCT01067053 |
Phase 2 |
bevacizumab, capecitabine, oxaliplatin |
16 |
A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma |
Unknown status |
NCT01552967 |
Phase 2 |
Capecitabine |
17 |
A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer |
Unknown status |
NCT04380103 |
Phase 1, Phase 2 |
XELOXIRI/Bevacizumab |
18 |
A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens |
Completed |
NCT00419159 |
Phase 2 |
Everolimus (RAD001) |
19 |
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma |
Completed |
NCT01900717 |
Phase 2 |
LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks |
20 |
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma . |
Completed |
NCT02788006 |
Phase 2 |
Regorafenib 160 mg |
21 |
Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70 |
Completed |
NCT00104689 |
Phase 2 |
capecitabine;oxaliplatin |
22 |
Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma |
Completed |
NCT00168155 |
Phase 2 |
perioperative chemotherapy |
23 |
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease |
Completed |
NCT00890305 |
Phase 2 |
CT-011;FOLFOX |
24 |
A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859) |
Completed |
NCT00574171 |
Phase 2 |
lapatinib;Capecitabine |
25 |
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver |
Completed |
NCT00149396 |
Phase 1, Phase 2 |
NV1020 |
26 |
A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma |
Completed |
NCT00034190 |
Phase 2 |
S-8184 Paclitaxel Injectable Emulsion |
27 |
A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma |
Completed |
NCT00025350 |
Phase 2 |
gefitinib |
28 |
Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma. |
Completed |
NCT02181465 |
Phase 2 |
|
29 |
A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies |
Completed |
NCT02870920 |
Phase 2 |
Tremelimumab;Durvalumab |
30 |
Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO |
Completed |
NCT01417494 |
Phase 2 |
Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab |
31 |
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors |
Completed |
NCT02599324 |
Phase 1, Phase 2 |
ibrutinib;everolimus;paclitaxel;docetaxel;cetuximab;pembrolizumab |
32 |
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer |
Completed |
NCT02292758 |
Phase 2 |
Irinotecan |
33 |
Regorafenib Assessment in Refractory Advanced Colorectal Cancer |
Completed |
NCT01929616 |
Phase 2 |
regorafenib |
34 |
Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus |
Completed |
NCT00597506 |
Phase 2 |
Bevacizumab;Everolimus |
35 |
A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma |
Completed |
NCT00165217 |
Phase 2 |
Capecitabine;Thalidomide |
36 |
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II) |
Recruiting |
NCT04117945 |
Phase 2 |
Irinotecan;Regorafenib |
37 |
A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients |
Recruiting |
NCT03087071 |
Phase 2 |
Trametinib |
38 |
A Phase 1b/2 Study of VS-6766 and Cetuximab in Patients With Advanced KRAS Mutated Colorectal Cancer |
Recruiting |
NCT05200442 |
Phase 1, Phase 2 |
VS-6766;Cetuximab |
39 |
A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. |
Recruiting |
NCT04483219 |
Phase 2 |
TKI ± anti-PD-1 antibody |
40 |
Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders |
Recruiting |
NCT04729322 |
Phase 2 |
Fecal Microbiota Transplantation Capsule;Metronidazole;Neomycin;Vancomycin |
41 |
An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression |
Recruiting |
NCT04826003 |
Phase 1, Phase 2 |
RO7122290;Cibisatamab;Obinutuzumab |
42 |
A Phase II Study Evaluating FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation |
Recruiting |
NCT03584711 |
Phase 2 |
|
43 |
Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors |
Recruiting |
NCT02185443 |
Phase 2 |
|
44 |
A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy |
Recruiting |
NCT04111172 |
Phase 2 |
|
45 |
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors |
Recruiting |
NCT04731467 |
Phase 1, Phase 2 |
CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion;CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion |
46 |
A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer |
Recruiting |
NCT04457284 |
Phase 2 |
Temozolomide (TMZ);Cisplatin;Nivolumab |
47 |
The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer |
Recruiting |
NCT03599752 |
Phase 2 |
Chemotherapy |
48 |
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine |
Recruiting |
NCT04894123 |
Phase 2 |
Trifluridine/Tipiracil;Oxaliplatin |
49 |
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line |
Recruiting |
NCT05312398 |
Phase 2 |
Cetuximab;FOLFIRI;FOLFOX regimen;Irinotecan |
50 |
A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer |
Recruiting |
NCT04474470 |
Phase 1, Phase 2 |
NT219;NT219 and ERBITUX® - Dose Escalation;NT219 and ERBITUX® - Expansion |
|